As reported earlier, Argus analyst John Eade upgraded Colgate-Palmolive to Buy from Hold with a price target of $72. The analyst says the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. Eade further states that his $72 price target implies a multiple of 21-times forward earnings, which is still below the midpoint of the company's historical range.

Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - U... To see the rest of the story go to thefly.com. See Story Here

Based on current spot rates: The company is raising its net sales growth guidance to 2% to 5% (versus 1% to 4% previously) including a mid-single-digit negative impact from foreign exchange (versus low-single-digit negative impact previously). FY24 revenue consensus $18.83B. The company is raising its organic sales growth guidance to 5% to 7% (versus 3% to 5% previously). On a GAAP basis, the company still expects gross profit margin expansion, increased advertising investment and double-digit earnings-per-share growth. On a non-GAAP (Base Business) basis, the company still expects gross profit margin expansion, increased advertising investment and mid to high-single-digit earnings-per-share growth.

Reports Q1 revenue $5.07B, consensus $4.63B. Noel Wallace, Chairman, President and Chief Executive Officer, commented on the Base Business first quarter results, "We are very pleased to have started 2024 with another quarter of strong top and bottom line performance as we continued to execute our strategy successfully. Net sales increased 6.2% and organic sales grew 9.8%, with organic sales growth in every division and across all categories. We are particularly pleased to have delivered double-digit growth in operating profit, net income and earnings per share for the third consecutive quarter while still investing for the long-term health of our business. The strong gross and operating margin expansion in the quarter funded a 16% increase in advertising and we expect strong levels of brand investment over the balance of 2024. We also continued to invest behind building and scaling the capabilities needed to drive our growth going forward, in areas like innovation, digital, data and analytics, revenue growth management and marketing effectiveness. Our strong growth momentum and great start to the year add to our confidence that we are executing the right strategies to deliver on our updated 2024 financial targets and generate consistent, compounded earnings per share growth."

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.